https://www.selleckchem.com/pr....oducts/chir-99021-ct
6 averted CRC cases and 1.1 averted cancer deaths per 100 than the CTC-based strategy, with an incremental cost-effectiveness ratio of US$55 500 per quality-adjusted life-year gained. Our analysis was most sensitive to the sensitivity of CTC for detecting polyps 10 mm or larger and assumptions about disease progression. In a simulation model, we found that replacing the standard-of-care approach to postdiagnostic surveillance with a CTC-based strategy is not an efficient use of resources in most situations. In a simulat
Like
Comment
Share
